Cover Image
市場調查報告書

Applied Genetic Technologies Corporation的產品平台分析

Applied Genetic Technologies Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224749
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Applied Genetic Technologies Corporation的產品平台分析 Applied Genetic Technologies Corporation - Product Pipeline Review - 2015
出版日期: 2015年12月16日 內容資訊: 英文 34 Pages
簡介

Applied Genetic Technologies Corporation是總公司在美國的製藥企業。開發、銷售色覺異常、老年性黃斑部病變、α1抗胰蛋白酵素缺乏症、萊伯氏先天性黑蒙症、X染色體連鎖性視網膜分離症等,稀少的肺部疾病及眼科疾病的治療藥。

本報告提供Applied Genetic Technologies Corporation 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Applied Genetic Technologies Corporation 基本資料

  • Applied Genetic Technologies Corporation 概要
  • 主要資訊
  • 企業資料

Applied Genetic Technologies Corporation :R&D概要

  • 主要的治療範圍

Applied Genetic Technologies Corporation :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Applied Genetic Technologies Corporation :開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Applied Genetic Technologies Corporation :藥物簡介

  • rAAV1-CB-hAAT
  • rAAV2-CB-hAAT
  • rAAV2-CB-hRPE65
  • Gene Therapy for Achromatopsia
  • Gene Therapy for Ophthalmology
  • Gene Therapy for Respiratory Disorders
  • Gene Therapy for X-linked Retinoschisis
  • Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa

Applied Genetic Technologies Corporation :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Applied Genetic Technologies Corporation :最近的開發平台資訊

Applied Genetic Technologies Corporation :開發休止的計劃

Applied Genetic Technologies Corporation :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07863CDB

Summary

Global Markets Direct's, 'Applied Genetic Technologies Corporation - Product Pipeline Review - 2015', provides an overview of the Applied Genetic Technologies Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Applied Genetic Technologies Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Applied Genetic Technologies Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Applied Genetic Technologies Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Applied Genetic Technologies Corporation's pipeline products

Reasons to buy

  • Evaluate Applied Genetic Technologies Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Applied Genetic Technologies Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Applied Genetic Technologies Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Applied Genetic Technologies Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Applied Genetic Technologies Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Applied Genetic Technologies Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Applied Genetic Technologies Corporation Snapshot
    • Applied Genetic Technologies Corporation Overview
    • Key Information
    • Key Facts
  • Applied Genetic Technologies Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Applied Genetic Technologies Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Applied Genetic Technologies Corporation - Pipeline Products Glance
    • Applied Genetic Technologies Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Applied Genetic Technologies Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Applied Genetic Technologies Corporation - Drug Profiles
    • Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Achromatopsia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for X-linked retinoschisis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rAAV2-CB-hAAT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Ophthalmology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Wet Age-related Macular Degeneration
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Cone Photoreceptor cGMP-Gated Channel for Achromatopsia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Applied Genetic Technologies Corporation - Pipeline Analysis
    • Applied Genetic Technologies Corporation - Pipeline Products by Target
    • Applied Genetic Technologies Corporation - Pipeline Products by Route of Administration
    • Applied Genetic Technologies Corporation - Pipeline Products by Molecule Type
    • Applied Genetic Technologies Corporation - Pipeline Products by Mechanism of Action
  • Applied Genetic Technologies Corporation - Recent Pipeline Updates
  • Applied Genetic Technologies Corporation - Dormant Projects
  • Applied Genetic Technologies Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Gene Therapy to Activate Retinal Pigment Epithelium 65 for Leber Congenital Amaurosis
  • Applied Genetic Technologies Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Applied Genetic Technologies Corporation, Key Information
  • Applied Genetic Technologies Corporation, Key Facts
  • Applied Genetic Technologies Corporation - Pipeline by Indication, 2015
  • Applied Genetic Technologies Corporation - Pipeline by Stage of Development, 2015
  • Applied Genetic Technologies Corporation - Monotherapy Products in Pipeline, 2015
  • Applied Genetic Technologies Corporation - Phase II, 2015
  • Applied Genetic Technologies Corporation - Phase I, 2015
  • Applied Genetic Technologies Corporation - Preclinical, 2015
  • Applied Genetic Technologies Corporation - Pipeline by Target, 2015
  • Applied Genetic Technologies Corporation - Pipeline by Route of Administration, 2015
  • Applied Genetic Technologies Corporation - Pipeline by Molecule Type, 2015
  • Applied Genetic Technologies Corporation - Pipeline Products by Mechanism of Action, 2015
  • Applied Genetic Technologies Corporation - Recent Pipeline Updates, 2015
  • Applied Genetic Technologies Corporation - Dormant Developmental Projects,2015
  • Applied Genetic Technologies Corporation - Discontinued Pipeline Products, 2015

List of Figures

  • Applied Genetic Technologies Corporation - Pipeline by Top 10 Indication, 2015
  • Applied Genetic Technologies Corporation - Pipeline by Stage of Development, 2015
  • Applied Genetic Technologies Corporation - Monotherapy Products in Pipeline, 2015
  • Applied Genetic Technologies Corporation - Pipeline by Top 10 Target, 2015
  • Applied Genetic Technologies Corporation - Pipeline by Top 10 Route of Administration, 2015
  • Applied Genetic Technologies Corporation - Pipeline by Top 10 Molecule Type, 2015
  • Applied Genetic Technologies Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top